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Abstract. Recent publications have emphasized the lack of characterization methods available for protein
particles in a size range comprised between 0.1 and 10 μm and the potential risk of immunogenicity
associated with such particles. In the present paper, we have investigated the performance of light
obscuration, ﬂow microscopy, and Coulter counter instruments for particle counting and sizing in protein
formulations. We focused on particles 2–10 μm in diameter and studied the effect of silicon oil droplets
originating from the barrel of pre-ﬁlled syringes, as well as the effect of high protein concentrations (up
to 150 mg/ml) on the accuracy of particle characterization. Silicon oil was demonstrated to contribute
signiﬁcantly to the particle counts observed in pre-ﬁlled syringes. Inconsistent results were observed
between different protein concentrations in the range 7.5–150 mg/ml for particles <10 μm studied by
optical techniques (light obscuration and ﬂow microscopy). However, the Coulter counter measurements
were consistent across the same studied concentration range but required sufﬁcient solution conductivity
from the formulation buffer or excipients. Our results show that currently available technologies, while
allowing comparisons between samples of a given protein at a ﬁxed concentration, may be unable to
measure particle numbers accurately in a variety of protein formulations, e.g., at high concentration in
sugar-based formulations.
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INTRODUCTION
A considerable emphasis has been put recently on sub-
visible particulate matter in protein pharmaceuticals. Pharma-
copeias only specify limits for sub-visible particles >10 μma n d
concerns have been expressed that sub-visible particles <10 μm
may present a signiﬁcant safety risk in terms of immunoge-
nicity (1–4). The extent of the safety risk is subject to debate
and needs to be further assessed (5) but nevertheless a gap has
been identiﬁed in analytical techniques for protein particles in
the size range 0.1–10 μm. If biological responses such as
immunogenicity are tentatively correlated to the size, nature,
or number of sub-visible particles, analytical tools that allow an
accurate characterization and quantitation of sub-visible partic-
ulate matter <10 μm in protein formulations would be needed.
Light obscuration, ﬂow microscopy, and the Coulter
counter are three commercially available particle-counting
techniques able to characterize particles >2 μm. The three
methods have been recently reviewed (6,7) and used in work
summarized in recent publications to study nucleation
phenomena in protein solutions (8,9). Flow microscopy has
received a lot of attention for the characterization of protein
formulations (10–12) while nanoparticle tracking analysis
(NanoSight) showed promising results for the characteriza-
tion of sub-micron particles in carefully chosen conditions
(13). The aim of the present work was to identify the
limitations of light obscuration, ﬂow microscopy, and the
Coulter counter when analyzing protein solutions. An
emphasis has been put on high-concentration solutions since
such formulations are increasingly being developed for
subcutaneous administration (14,15), an administration route
especially prone to trigger immune responses (3). In addition,
these high-concentration samples have been evaluated after
storage in pre-ﬁlled syringes coated with silicone oil. Potential
interferences in analysis and detection of particulates due to
the presence of silicon oil droplets are also discussed.
MATERIALS AND METHODS
Materials
MAb1 is a recombinant humanized IgG1 with a κ light
chain and is expressed in Chinese hamster ovary cells at
Genentech, Inc. (South San Francisco, CA, USA). The
MAb1 drug substance was formulated at 150 mg/ml in
20 mM histidine hydrochloride, 200 mM arginine hydro-
chloride, 0.04% polysorbate 20 at pH 6.0 and stored at −70°C
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3 days at 2–8°C in 1-ml BD pre-ﬁlled syringes coated with
silicon oil (“MAb1 drug substance in pre-ﬁlled syringes”)
or >6 years at 2–8°C in 1-ml BD pre-ﬁlled syringes coated
with silicon oil (“aged MAb1 pre-ﬁlled syringes”). For the
comparison of light obscuration, ﬂow microscopy, and the
Coulter counter methods, the contents of ~25 aged MAb1
pre-ﬁlled syringes were pooled and mixed in an Accuvette ST
container (Beckman Coulter, Fullerton, CA, USA). The
pooled solution was diluted with formulation buffer to 45,
30, 15, and 7.5 mg/ml in separate Accuvette ST containers.
Each solution (including the formulation buffer alone) was
analyzed ﬁrst on the Coulter counter, then on the ﬂow
microscopy instrument and ﬁnally on the light obscuration
counter. All measurements were performed the same day,
from the same container, in triplicate (see below).
To test the limits of the instruments in terms of viscosity
and conductivity, MAb1 was also formulated at 125 mg/ml in
15 mM histidine hydrochloride, 255 mM sucrose, 0.03%
polysorbate 20 at pH 6.0 (“low conductivity MAb1 solution”).
The viscosity of the low-conductivity MAb1 solution
was ~80 mPa·s at room temperature. The low-conductivity
MAb1 solution was diluted in formulation buffer to 20 and
1 mg/ml MAb1 to evaluate the response of the instruments
upon dilution.
Protein X is a recombinant human protein produced in E.
coli at Genentech, Inc. Protein X was formulated at 5 mg/ml
and degraded by 1-year storage at 2–8°C in the presence of
signiﬁcant levels of silicon oil (0.2–0.3 mg silicon oil/ml of
Protein X solution).
Light Obscuration
Light obscuration measurements were performed on a
HIAC Royco Liquid Particle Counting System Model 9703
with sensor model HRLD-150 and sampler model 3000A,
equipped with a 1-ml syringe (Hach Company, Loveland, CO,
USA). The light obscuration instrument was placed in a
laminar ﬂow hood. The performance of the instrument was
veriﬁed using 10 μm polystyrene count and size standards
(Thermo Scientiﬁc, Fremont, CA, USA). For each protein
solution and formulation buffer, four 1-ml aliquots were
sampled at a speed of 10 ml/min; the ﬁrst aliquot was
discarded and the results of the three following aliquots were
averaged. The aliquots differ signiﬁcantly from the USP
method and were chosen to reduce the sample volume
needed to perform the measurements. Other authors have
shown that small sampling volumes are appropriate for
quantifying size and levels of sub-visible particles at the
amounts typically present in protein therapeutics (16,17). All
light obscuration measurements (total counts >2 μm uncor-
rected for the dilution factor) were well below the upper
count limit of 18,000 particles/ml.
Flow Microscopy
Flow microscopy measurements were performed on a
DPA4100 series B Micro-Flow Imaging™ instrument (Bright-
well Technologies Inc., Ottawa, Canada) equipped with a
computer-controlled peristaltic pump and a low magniﬁcation,
400-μm-deep ﬂow cell. The ﬂow microscope was placed in a
laminar ﬂow hood. The performance of the instrument was
veriﬁed using 10 μm polystyrene count and size standards. For
each protein solution and the formulation buffer, a 1-ml aliquot
was used as following: 0.22 ml was used to ﬂush the ﬂow cell,
0.1–0.2 ml was used to optimize the illumination and 0.5 ml was
analyzed. Two subsequent 1-ml aliquots were used as follows:
0.22 ml was used to ﬂush the ﬂow cell and 0.7 ml was analyzed.
The three measurements were averaged.
Coulter Counter
Coulter counter measurements were performed on a
Multisizer 4 instrument equipped with a 100-μm aperture
(Beckman Coulter, Fullerton, CA, USA). The inside of the
aperture tube was ﬁlled with Isoton II Diluent (Beckman
Coulter, Fullerton, CA, USA). Standards as well as samples
were analyzed in Accuvette ST containers (Beckman Coulter,
Fullerton, CA, USA). The aperture tube calibration was
checked daily with 10-μm latex size standards diluted in
Isoton II. Each protein solution or formulation buffer was
transferred into a clean Accuvette ST container before
measurement and three 1-ml aliquots were analyzed and
averaged.
For the measurements of the low-conductivity MAb1
solution (see Materials), the inside of the aperture tube was
ﬂushed with formulation buffer (15 mM histidine hydro-
chloride, 255 mM sucrose, 0.03% polysorbate 20 at pH 6.0).
The aperture tube calibration was performed with size
standards diluted in the formulation buffer. To accommodate
for the high-viscosity samples (80 mPa·s), the instrument
vacuum was set to 6.5 in. of mercury and the minimum ﬂow
was set to 5 μl/s.
Microscopy
Particle counts were assessed by the USP Chapter 788
“Microscopic particle count test” with the following modiﬁ-
cations: 10–11 ml of each protein solution (or formulation
buffer) was pooled and ﬁltered; particles >5, >10, and >25 μm
were counted and reported.
Refractive Index Measurements
The refractive index of the buffers and protein solutions
was determined at 20°C on a LR-01 refractometer (Maselli
misure, Milan, Italy). Temperature control (± 0.03°C) was
provided by an Isotemp 3015 S recirculating water bath
(Fisher Scientiﬁc, Waltham, MA, USA). Three measurements
were averaged for each sample.
Viscosity Measurements
The viscosity of protein solutions was measured at 25°C
on a MCR300 rheometer (Anton Paar, Graz, Austria) as
described previously (18). Brieﬂy, the samples were allowed
to reach thermal equilibrium and then went through two
cycles of shear rate sweeps ranging from 10 to 1,000 s
−1.W e
reported the mean viscosity at a shear rate of 1,000 s
−1.
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Known Operating Limitations of Particle-Counting
Instruments
Light obscuration, ﬂow microscopy, and Coulter counter
instruments are based on different principles and therefore
require different operating conditions. All three techniques
are intended for low-viscosity samples (with the exception of
the Coulter counter equipped with larger apertures, a case
irrelevant to the discussion).
Light obscuration instruments are used to characterize
particles >2 μm and provide quick measurements with a
drawing speed of 10 ml/min for the conﬁguration described in
MATERIALS AND METHODS. They are however limited
to a total particle count of 18,000 particles/ml; samples may
need to be diluted to fall within this range.
Flow microscopy (in low-magniﬁcation mode) measures
particles >2 μm. Flow microscopy's particle count limit is much
higher than light obscuration's: the DPA4100 instrument
described in MATERIALS AND METHODS is able to
characterize solutions containing up to 275,000 particles/ml
(2.5-μm particles) or 125,000 particles/ml (5-μmp a r t i c l e s )o r
30,000 particles/ml (10-μm particles). Flow microscopy also has
imaging capabilities which may be useful in the character-
ization of irregular particles (19). Figure 1 shows that for a
heavily aggregated protein sample, ﬁbrillar particles of length
close to 100 μm can be reported as a spherical particle having
an equivalent circular diameter of ~20 μm; other authors have
presented a more detailed analysis of this phenomenon (10,11).
Light obscuration and Coulter counters only report equivalent
diameters without any information on morphology; therefore,
they would not describe ﬁbrillar particles accurately. Shape
parameters are beneﬁcial for sample characterization, even
though only a 2-D projection of the particle is available.
Coulter counters measure particles in a size range
deﬁned by the aperture size that is used. We used a 100 μm
aperture, which allows particles 2–60 μm in diameter to be
counted and characterized. Larger particles may block the
aperture. Since the Coulter principle is based on impedance
measurements, the optical properties of the sample are
irrelevant but the sample must be dispersed in an electrolyte.
The formulation buffer of MAb1 provided enough conduc-
tivity for Coulter counter measurements due to the presence
of 200 mM arginine hydrochloride and 20 mM histidine
chloride but other formulation buffers (e.g., sugar-based) may
not be used directly. Dilution in stronger electrolytes (e.g.,
saline or Isoton II diluent) is possible but may change the
properties and particle size distribution of the solution. The
sensitivity of the protein to dilution in high-conductivity
buffers has to be evaluated on a case-by-case basis.
Interference from Non-Particulate Matter: Silicon Oil
The barrel of glass pre-ﬁlled syringes is usually coated
with silicon oil to facilitate the motion of the plunger. In order
to evaluate the impact of the silicon oil coating on particle
counts, MAb1 drug substance was incubated for 3 days at 2–
8°C in 1-ml preﬁllable glass syringes. The resulting particle
count was compared to the fresh drug substance as well as to
MAb1 pre-ﬁlled syringes aged for >6 years at 2–8°C. Figure 2
shows an increase in particle counts by ﬂow microscopy after
3 days of exposure to a siliconized syringe barrel at 2–8°C; the
increase was even more pronounced after prolonged storage.
The same trends were observed by light obscuration (data not
shown). An increase in particle counts was observed for both
the formulation buffer and the MAb1 drug substance stored
in preﬁllable syringes when compared to storage in vials; the
increase in particle counts was however more pronounced for
MAb1 drug substance. Our hypothesis is that the increase in
particle counts was due to silicon oil sloughing off of the
syringe barrels as opposed to protein particle formation. The
higher number of particles counted after a short-time
exposure of the MAb1 drug substance to siliconized syringe
barrels can be explained by the signiﬁcant surface activity of a
concentrated antibody solution (20). Upon longer-term
Fig. 1. Irregular shape of protein particles determined by ﬂow
microscopy. Protein X was degraded by high-temperature storage in
the presence of signiﬁcant levels of silicon oil. Fibrillar particles with a
largest dimension (Feret diameter) of close to 100 μm showed a
corresponding equivalent circular diameter of ~20 μm
Fig. 2. Inﬂuence of silicon oil on particle counts determined by ﬂow
microscopy. DS, drug substance; PFS, pre-ﬁlled syringes. Results are
reported as average±standard deviation. Storage of the formulation
buffer and drug substance for 3 days in pre-ﬁlled syringes (MAb1 DS
in PFS) resulted in a signiﬁcant increase in particle counts. Pre-ﬁlled
syringes stored for >6 years (Aged MAb1 PFS) showed an even
higher particle count (note the axis break)
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formed. In order to prove that the increase in particle counts
was due to silicon oil sloughing off of the syringe barrels, a
slightly modiﬁed USP Chapter 788 “Microscopic particle
count test” was performed on all solutions (see MATERIALS
AND METHODS). Silicon oil droplets are not retained by or
visible on the ﬁlter and therefore only particulate matter is
counted by the microscopic particle count test (21). Figure 3
shows that the modiﬁed USP Chapter 788 microscopic
particle count test found similar levels of particulate matter
in all samples. The similar level of particulate matter
observed between MAb1 drug substance stored in vials and
stored in pre-ﬁlled syringes indicates that the silicon oil was
indeed not visible on the ﬁlter. The similar level of particulate
matter observed between the MAb1 drug substance after
3 days and >6-years storage in pre-ﬁlled syringes at 2–8°C
show that the increase in particle counts observed by light
obscuration and ﬂow microscopy in pre-ﬁlled syringes can be
attributed to silicon oil droplets and not particulate matter
(proteinaceous or not).
The Effect of Protein Concentration on Particle Counts
An increasing number of therapeutic proteins, especially
monoclonal antibodies, are now formulated at high concen-
trations (150 mg/ml and more) (14,15). We investigated the
effect of high protein concentration on three particle-counting
methods: Coulter counter, light obscuration, and ﬂow micro-
scopy. As described in MATERIALS AND METHODS,
MAb1 solutions at 150 mg/ml stored in pre-ﬁlled syringes
were diluted to concentrations ranging from 7.5 to 150 mg/ml
and the particle counts obtained from Coulter counter, ﬂow
microscopy, and light obscuration were compared. As
described in the previous section, most of the particle counts
can be attributed to silicon oil droplets. Shape analysis of the
particles >5 μmb yﬂow microscopy also supports the
attribution of the counts to silicon oil, e.g., in the 15 mg/ml
solution >80% of the particles ≥5 μm had an aspect
ratio ≥0.85. Once samples are withdrawn from the pre-ﬁlled
syringes, silicon oil droplets should give consistent counts
after dilution, i.e., two times dilutions should result in half the
counts since dilution in the presence of surfactant (polysor-
bate 20 from the formulation buffer) is not expected to alter
the stability of the emulsion. Figures 4, 5, and 6 present the
particle counts in the 150 mg/ml stock solution, determined at
several dilution levels. Since the data are corrected for the
dilution factor, the instruments were expected to show the
same particle counts in all conditions. Figure 4 shows counts
of particles 10.25 μm and larger. Relatively large standard
deviations are observed that can be attributed to the low
particle counts in the solutions; e.g., in the case of the 7.5-mg/
ml solution, the raw particle count from the Coulter counter
was 96 particles/ml, which corresponds to 1,920 particles/ml in
the stock solution once multiplied by the dilution factor (20).
The uncertainty on a 96 particles/ml measurement translates
to a larger error on the dilution-corrected count. With the
exception of the light obscuration measurement performed at
150 mg/ml, the values from the three instruments are in
reasonable agreement.
Figure 5 shows counts of particles 3.5 μm and larger. The
Coulter counter gave consistent measurements across the
studied protein concentrations. Up to 45 mg/ml, ﬂow micro-
scopy gave results similar to the Coulter counter but showed
lower counts at 150 mg/ml. Light obscuration reported lower
particle numbers that both the Coulter counter and ﬂow
Fig. 3. Inﬂuence of silicon oil on particle counts determined by a
modiﬁed version of the USP Chapter 788 “Microscopic particle count
test”. DS, drug substance; PFS, pre-ﬁlled syringes. Silicon oil droplets
are not retained by the ﬁlter. Similar counts were obtained for the
drug substance before and after storage in pre-ﬁlled syringes, as well
as for the pre-ﬁlled syringes stored >6 years at 2–8°C (Aged MAb1
PFS). The increase in particle numbers observed by ﬂow microscopy
and light obscuration upon storage in pre-ﬁlled syringes can be
attributed to silicon oil droplets and not to protein (or extraneous)
particles
Fig. 4. Comparing the performance of Coulter counter, ﬂow micro-
scopy, and light obscuration instruments for particles >10.25 μmi n
protein solutions. Results are reported as average±standard devia-
tion. Counting was performed at several protein concentrations; the
reported particle numbers have been corrected for the dilution factor
and represent the particle content of the stock (150 mg/ml) solution.
The three instruments reported similar results, with the exception of
light obscuration which underestimated the particle numbers when
performing the measurement at 150 mg/ml. The particle counts of the
formulation buffer are included (0 mg/ml)
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larger. Again, the Coulter counter gave consistent results for
protein concentrations ranging from 7.5 to 150 mg/ml. Both
light obscuration and, to a lesser extent, ﬂow microscopy
counted less particles than the Coulter counter. Both optical
techniques showed a similar trend: lower counts were
reported at high protein concentrations.
Optical techniques (light obscuration and ﬂow micro-
scopy) tended to report lower particle numbers than the
Coulter counter, especially for smaller particles sizes and
higher protein concentrations. The lower sensitivity of optical
techniques probably arises from a lower contrast typical of
high-concentration protein formulations (19). The contrast
that allows optical detection of particles is caused by a
difference in refractive index between the particle and the
surrounding medium. The refractive index of the particles
does not change but the refractive index of the surrounding
medium increases with an increasing (monomeric) protein
concentration, thus reducing the difference in refractive index
and therefore contrast. In the case of MAb1, the formulation
buffer has a refractive index of 1.3419, the 150 mg/ml MAb1
formulation has a refractive index of 1.37151 and the silicon
oil that is responsible for most of the particle counts in this
particular sample has a refractive index of 1.4042. From 0 to
150 mg/ml, the difference in refractive index (contrast) drops
from 0.0623 to 0.0327. The refractive index of protein
particles is likely comprised between 1.4 and 1.6 but the
detection of protein particles may be further compromised by
their irregular shape and indistinct edges (19). Sharma et al.
have shown that light obscuration was more affected than
ﬂow microscopy by low contrast between the particles and
the surrounding buffer (12), which is consistent with our
ﬁndings that light obscuration detected less particles than
ﬂow microscopy for most particle sizes.
We hypothesize that optical techniques are likely to be
undercounting particles (rather than the Coulter counter
overestimating the particle count), based on the good agree-
ment between ﬂow microscopy and Coulter counter—two
orthogonal techniques—at low concentrations and for larger
particle sizes. The reduced contrast in solutions of high
protein concentration can explain the lower counts observed
by optical techniques. It is worth noting that the charge of the
particles has no impact on the Coulter counter measurements
(22). Nevertheless, despite the good agreement between the
Coulter counter and ﬂow microscopy under certain condi-
tions, there is no assurance that the particle counts reﬂect the
true number of particles in solution.
The Effect of Solution Viscosity and Conductivity
The MAb1 samples formulated in the arginine-containing
buffer had a viscosity of ~12 mPa·s at 150 mg/ml and 25°C, and
the 200 mM arginine hydrochloride provided ample conduc-
tivity for the Coulter counter measurements. A low-conductiv-
ity MAb1 solution (see MATERIALS AND METHODS)w a s
used to test the limits of the instruments with regards to
solution viscosity and conductivity. Neither light obscuration
nor ﬂow microscopy was able to handle the low-conductivity
sample due to its high viscosity (80 mPa·s), i.e., the speciﬁed
ﬂow rates could not be maintained. The Coulter counter,
however, was able to analyze the solution, despite its low
conductivity and high viscosity. The low conductivity of the
Fig. 5. Comparing the performance of Coulter counter, ﬂow micro-
scopy, and light obscuration instruments for particles >3.5 μmi n
protein solutions. Results are reported as average±standard devia-
tion. Counting was performed at several protein concentrations; the
reported particle numbers have been corrected for the dilution factor
and represent the particle content of the stock (150 mg/ml) solution.
The Coulter counter gave consistent measurements across the studied
protein concentrations. Up to 45 mg/ml, ﬂow microscopy gave results
similar to the Coulter counter but showed lower counts at 150 mg/ml.
Light obscuration reported lower particle numbers than both ﬂow
microscopy and the Coulter counter in all the solutions. The particle
counts of the formulation buffer are included (0 mg/ml)
Fig. 6. Comparing the performance of Coulter counter, ﬂow micro-
scopy, and light obscuration instruments for particles >2.75 μmi n
protein solutions. Results are reported as average±standard devia-
tion. Counting was performed at several protein concentrations; the
reported particle numbers have been corrected for the dilution factor
and represent the particle content of the stock (150 mg/ml) solution.
The Coulter counter gave consistent measurements across the studied
protein concentrations. Both optical methods (ﬂow microscopy and
light obscuration) reported lower particle numbers than the Coulter
counter. The particle counts of the formulation buffer are included
(0 mg/ml)
712 Demeule et al.sample was reﬂected in an aperture resistance of up to 320 kΩ.
The increased resistance imparted a higher noise level in the
measurements, resulting in the smallest measurable size
increasing from 2 to 2.36 μm on a 100-μm aperture. The
higher viscosity was dealt with by increasing the vacuum in the
instrument lines as well as decreasing the ﬂow rate (see
MATERIALS AND METHODS). Figure 7 shows the particle
counts in the 125 mg/ml low-conductivity solution, determined
at several dilution levels. Consistent with our previous
observations on arginine-containing MAb1 solutions (Figs. 4,
5,a n d6), the Coulter counter gave consistent measurements
across the studied protein concentrations. The higher standard
deviations observed at low concentrations are due to the low
particle counts, as discussed above.
DISCUSSION
Interference from Silicon Oil
We have shown that silicon oil could be a major source of
particle counts when protein formulations were stored in pre-
ﬁlled syringes. Similar phenomena were observed in the past
with silicon oil sloughing off of rubber stoppers (21,23).
Differences in protein particle numbers will be difﬁcult to
assess in the presence of a large amount of counts due to
silicon oil. Like air bubbles, silicon oil droplets could be
distinguished from proteinaceous particles based on their
spherical shape. Morphological assessments of the particles
are however limited to imaging techniques (ﬂow microscopy)
and based on the assumption that protein or extraneous
particles are not spherical; few orthogonal techniques are
available to conﬁrm the assignment of the counts to silicon
oil. We have used a modiﬁed version of the USP Chapter 788
“Microscopic particle count test” (Fig. 3) to show that the
increase in particle counts observed in pre-ﬁlled syringes
(Fig. 2) was due to silicon oil. Direct comparison of particle
counts obtained by the USP microscopy method and light
obscuration (or ﬂow microscopy) is however not possible
even in the absence of silicon oil due to the differences in
sensitivity between the methods (emphasized by the different
acceptance criteria deﬁned in the USP Chapter 788).
The presence of silicon oil droplets allowed an efﬁcient
testing of the light obscuration, ﬂow microscopy, and Coulter
counter instruments. As discussed in the RESULTS section,
silicon oil droplets differ from protein particles in terms of shape
and to some extent refractive index. Despite the differences
between silicon oil and protein particles, testing the instruments
on protein particles is not necessarily feasible because particles
are typically present in very small numbers in fresh protein
formulations, which translates to higher errors in counting and
more difﬁculty in comparing samples. The high number of
silicon oil droplets has not contributed to the inferior perform-
ance of the light obscuration instrument, which is limited to
18,000 particles/ml: at low or high protein concentrations, the
raw particle counts are well within the limits of the instrument
e.g., at 7.5 mg/ml the particle count of 22,140 (corrected for the
dilution factor) was obtained from a raw count of 1,107
particles/ml (dilution factor=20; 1,107·20=22,140). All light
obscuration measurements (total counts >2 μm uncorrected for
the dilution factor) were well below the limit of 18,000 counts/
ml. Generation of an artiﬁcially high number of protein particles
(e.g., by shaking) is feasible but in the authors' experience
produce unstable suspensions that show counts decreasing
with time and increasing or decreasing with dilution. The
silicon oil droplets allowed us to characterize the effect of
protein concentration on particles counts. On the one hand,
characterization of protein particles could be slightly easier
due to the potentially higher refractive index of protein
particles; on the other hand, characterization could be more
difﬁcult due to the irregular shape and indistinct edges
typical of protein particles.
The Effect of Protein Concentration
Our data suggest that protein concentrations as low
as ~10 mg/ml can impair the detection and characterization of
particles <10 μm by optical techniques. Discrepancies
between particle-counting techniques have been documented
in the past (24). Light obscuration and ﬂow microscopy
showed different sensitivities to protein concentration. Con-
sequently, analyzing a protein formulation at tens of milli-
grams per milliliter or more by optical techniques without
dilution will not yield accurate particle numbers <10 μm,
although trends can be compared. Dilution is not necessarily
a viable option since the process may create or disrupt
particles or may result in very low counts, making compar-
isons difﬁcult. In the case of MAb1, the Coulter counter was
an appropriate method for particle analysis due to the high
conductivity of the arginine-based formulation buffer. Other
buffers may not be equally suited to Coulter counter
measurements and dilution in saline or other conductive
solutions will raise the question of potential sample alter-
Fig. 7. Particle counts of a low-conductivity, high-viscosity protein
solution measured with the Coulter counter. Results are reported as
average±standard deviation. The error bars are smaller than the
symbol in two instances (0 and 125 mg/ml). Counting was performed
at several protein concentrations; the reported particle numbers have
been corrected for the dilution factor and represent the particle
content of the stock (125 mg/ml) solution. The Coulter counter gave
consistent measurements across the studied protein concentrations,
despite the low conductivity (15 mM histidine acetate) and high
viscosity (80 mPa·s). The particle counts of the formulation buffer are
included (0 mg/ml)
713 Challenges in Counting Protein Particlesations caused by changes in solution conditions and the
sample preparation process.
Given the difﬁculty to obtain accurate particle counts <10 μm
in protein solutions, utmost care must be exercised when
comparing particle numbers from different instruments, different
proteins, or even the same protein at different concentrations, or
when trying to correlate particle numbers with biological
parameters such as immunogenicity. Particle-counting tech-
niques are reaching the limits of their capabilities with protein
samples and the analyst must recognize that some samples,
especially high-concentration protein formulations, may be
extremely challenging to characterize accurately with regards
to particle counts.
The Effect of Solution Viscosity and Conductivity
We have observed that a high solution viscosity could
compromise measurements on current light obscuration and
ﬂow microscopy instruments. Viscosity was less of an obstacle
for Coulter counter measurements, mostly because the instru-
ment can readily be conﬁgured to handle lower ﬂow rates.
There is however a limit to the viscosity that the instrument
can handle, which was not determined in our study. Surpris-
ingly, the Coulter counter performed well for this sample
even though we performed measurements at conductivities
well below the manufacturer's recommendation. Such mea-
surements must be performed in carefully controlled con-
ditions, where the whole instrument is ﬁlled with the low-
conductivity formulation buffer and the calibration is also
performed in formulation buffer. The conductivity of the
buffer dictates the minimal size that can be measured with the
Coulter counter.
CONCLUSION
Particle-counting techniques described in the current
paper are well established and have been shown to provide
useful information about protein particles with many samples.
Nevertheless, protein particles, especially in high-concentration
protein formulations, were shown to pose speciﬁc challenges
to optical-based particle-counting techniques: light obscura-
tion and ﬂow microscopy. The low refractive index of
protein particles combined with an increased refractive
index of the background due to the high protein concen-
tration resulted in a signiﬁcant underestimation of the
particle numbers. While comparisons can be performed in
well-deﬁned conditions (e.g., to compare two formulations
of the same protein at the same concentration), more
quantitative measurements of particulate matter <10 μmi n
protein formulations can only be performed by optical
techniques at protein concentrations below 10 mg/ml.
Dilution may also introduce artifacts, especially if particle
formation is concentration-dependant. The Coulter counter
was shown to perform adequately over a large protein
concentration range (7.5–150 mg/ml) and provided an
orthogonal approach to light obscuration or ﬂow microscopy
as long as the formulation buffer was conductive enough. Due
to the aforementioned limitations, accurate determination, and
characterization of protein sub-visible particles remains a
challenging and difﬁcult task. New methods or procedures
need to be developed to help us better understand the issue of
sub-visible particles in protein pharmaceuticals.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which
permits any noncommercial use, distribution, and reproduction in
any medium, provided the original author(s) and source are
credited.
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